Projects

View
Name NEURONET
Long Name Efficiently Networking European Neurodegeneration Research
Description Efficiently Networking European Neurodegeneration Research. NEURONET is the Coordination and Suport Action for IMI’s growing neurodegenerative disorders (ND) portfolio. NEURONET aims to be a key enabler and mediator across the portfolio, assisting in identifying gaps, multiplying impacts, enhancing visibility and ensuring coordination with related initiatives in Europe and worldwide. The mapping of ND actions and initiatives is among NEURONET’s objectives, as is providing coordination and support to the individual IMI projects, management support to the whole programme, and the identification and dissemination of best practices and learnings. NEURONET hopes to help IMI’s ND projects to create a platform for the efficient collaboration of current and future IMI ND projects, thus helping them to make progress and deliver results that will benefit the millions of people who live with neurodegenerative diseases.
Objectives 1. Creation of an overall platform for efficient collaboration, communication and operational synergies among present and future IMI neurodegenerative diseases projects. 2. Designing systems to map and analyse information regarding actions, initiatives and partnerships, assessing impact of the individual projects, remaining gaps and global value of the programme for stakeholders. 3. Supporting the management of the programme (timelines, dependencies, synergies and key results across projects). 4. Proactively detecting needs, opportunities and transferable best practices of projects. 5. Providing support to the projects by organising tools, services, expert advice and guidelines/recommendations on common issues. 6. Promoting enhancement and coordination of communication across the IMI neurodegeneration projects, increasing programme visibility, outreaching to key stakeholders and establishing relationships with initiatives in the field. 7. Preparing and securing the long-term sustainability of Neuronet itself. (source: Neuronet website)
Website http://imi-neuronet.org/
Start date 01-03-2019
End date 31-08-2022
Logo
Name Projects Type of institution Country  
Synapse Research Management Partners SL EPAD AMYPAD NEURONET EMIF ROADMAP SME Spain
Janssen Pharmaceutica NV EPAD ADAPTED AMYPAD IMPRiND EQIPD NEURONET EMIF IM2PACT PHAGO PRISM RADAR-CNS RADAR-AD ROADMAP IDEA-FAST Pharma-Cog EPND EFPIA Belgium
National Institute For Health And Care Excellence NEURONET ROADMAP HTA body/Regulatory agency United Kingdom
Parkinson's Disease Society Of The United Kingdom LBG NEURONET PD-MitoQUANT IDEA-FAST PD-MIND Patient/carers organisation United Kingdom
Alzheimer Europe EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD ROADMAP NEURONET Pharma-Cog EPND Patient/carers organisation Luxembourg
Eli Lilly And Company Ltd EPAD IMPRiND MOPEAD PHAGO PRISM RADAR-AD ROADMAP NEURONET IDEA-FAST Pharma-Cog EFPIA United Kingdom
F. Hoffmann-La Roche AG EPAD EQIPD EMIF PHAGO PRISM ROADMAP NEURONET IDEA-FAST Pharma-Cog EPND EFPIA Switzerland
Sanofi-Aventis Recherche & Developpement EPAD EQIPD AETIONOMY IM2PACT PHAGO NEURONET Mobilise-D IDEA-FAST EPND EFPIA France
Takeda Pharmaceuticals International AG EPND EPAD PRISM RADAR-AD ROADMAP IDEA-FAST Mobilise-D NEURONET EFPIA Switzerland
WP number Description Project  
WP1 Projects & impact analysis NEURONET
WP2 Programme integration NEURONET
WP3 Tools & services NEURONET
WP4 Dissemination & outreach NEURONET
WP5 CSA Management & sustainability NEURONET
Deliverable number Title Project Submission date Link Keywords  
D3.4 First version of guidance on standards and practices for protecting data privacy NEURONET 02-03-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/03/D3.4_NEURONET_website.pdf
D4.2 Public event proceedings and videos – Year 1 NEURONET 27-02-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/02/NEURONET_D4.2-Public-event-proceedings-and-videos-Year-1-final.pdf
D3.5 First version of guidance on sustainability NEURONET 16-06-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/06/NEURONET_D3.5_SUSTAINABILITY_Final.pdf Neuronet, guidance, sustainability, IMI, funding
D3.2 First version of guidance tools on data/sample sharing and use NEURONET 04-06-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/06/NEURONET_D3.2_final.pdf
D2.2 Report #1 on activity of SCB, WGs and TFs NEURONET 27-03-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/04/Neuronet-D2.2.pdf
D1.3 Map of relevant initiatives and gap analysis NEURONET 26-03-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/04/Neuronet-D1.3-1.pdf
D1.2 Integrated programme analysis v1 NEURONET 25-04-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/04/NEURONET_D1.2_Final-3.pdf
D1.4 First report on impact of IMI neurodegeneration portfolio NEURONET 10-11-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/11/D1.4-First-report-on-impact-of-IMI-neurodegeneration-portfolio.pdf
D2.1 Report on establishment and procedures of SCB and foundational WGs NEURONET 13-06-2019 https://www.imi-neuronet.org/wp-content/uploads/2020/04/NEURONET_D2.1.pdf
D3.1 INKB web platform v1: NEURONET Knowledge Base v1 NEURONET 29-08-2019 https://www.imi-neuronet.org/wp-content/uploads/2019/08/NEURONET_D3.1_v1.3_Final.pdf
D3.3 First version of regulatory/HTA/payer interaction decision tool NEURONET 24-12-2019 https://www.imi-neuronet.org/wp-content/uploads/2020/04/NEURONET_D3.3.pdf
D3.6 INKB web platform v2: The NEURONET Knowledge Base v2 NEURONET 31-08-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/09/NEURONET_D3.6_final.pdf
D4.1 NEURONET communication strategy NEURONET 14-08-2019 https://www.imi-neuronet.org/wp-content/uploads/2020/04/NEURONET_D4.1.pdf
D4.3 Interim report on dissemination activities NEURONET 31-08-2020 https://www.imi-neuronet.org/wp-content/uploads/2020/09/NEURONET_D4.3_vFinal.pdf
D5.1 Initial Data & Knowledge Management Plan NEURONET 29-08-2019 https://www.imi-neuronet.org/wp-content/uploads/2020/04/NEURONET_D5.1_V1.2_Final.pdf
D1.1 Project outreach and analysis package NEURONET 26-11-2019 https://www.imi-neuronet.org/wp-content/uploads/2020/04/NEURONET_D1.1.pdf
D4.4 Public event proceedings and videos –Year 2 NEURONET 26-02-2021 https://www.imi-neuronet.org/wp-content/uploads/2021/03/NEURONET_D4.4-Public-event-proceedings-and-videos-Year-2-final.pdf
D5.2 Action plan from the IMI review and updates to the Data and Knowledge Management Plan NEURONET 05-10-2020 https://www.imi-neuronet.org/wp-content/uploads/2021/05/D5.2-Action-plan-from-the-IMI-review-and-updates-to-the-Data-and-Knowledge-Management-Plan.pdf
D5.3 Interim NEURONET sustainability report NEURONET 09-03-2021 https://www.imi-neuronet.org/wp-content/uploads/2021/05/NEURONET_D5.3_so.pdf
D2.3 Report #2 on activity of SCB, WGs and TFs. NEURONET 04-06-2021 https://www.imi-neuronet.org/wp-content/uploads/2021/06/D2.3-Report-2-on-activity-of-SCB-WGs-and-TFs.pdf
D1.5 Integrated programme analysis v2 NEURONET 01-03-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/03/NEURONET_D1.5-Final-Version.pdf
D1.6 Map of relevant initiatives and gap analysis v2 NEURONET 01-03-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/03/Neuronet-D1.6-v0.3_Final-version.pdf
D4.5 Public event proceedings and videos – Year 3 NEURONET 01-03-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/03/NEURONET_D4.5-2.0-Final-Version.pdf
D3.7 Final version on guidance tools on data/sample sharing and use NEURONET 02-03-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/03/NEURONET_D3.7_v1.0-Final-Version.pdf
4.6 Final report on dissemination and outreach activities (including impact measures) NEURONET 31-08-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/09/NEURONET_D4.6_Final.pdf
3.9 Final version of guidance on standards and practices for protecting data privacy NEURONET 31-08-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/09/NEURONET_D3.9_Final.pdf
1.8 White paper on project impact analysis NEURONET 31-08-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/09/NEURONET_D1.8-_Final.pdf
3.11 White paper on regulatory, HTA, and payer strategy for neurodegenerative diseases NEURONET 31-08-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/09/NEURONET_D3.11_Final-1.pdf
1.7 Final report on impact of IMI neurodegeneration portfolio NEURONET 07-11-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/12/D1.7-v1.6-Final_IMI_Submission.pdf
2.4 Report #3 on activity of SCB, WGs and TFs NEURONET 08-11-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/12/20221108_D2.4-v1.0_Final.pdf
D3.10 Final version of sustainability guidance NEURONET 10-11-2022 https://www.imi-neuronet.org/wp-content/uploads/2022/12/NEURONET_D3.10_v1.0_Final.pdf
Title First author last name Year Project Link Keywords  
The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks O'Rourke 2022 NEURONET https://doi.org/10.3389/fneur.2022.994301
Avoiding fragmentation: The potential of synergistic efforts across the IMI portfolio Diaz 2022 NEURONET https://doi.org/10.3389/fneur.2022.1050360 neurodegeneration, public-private partnerships, cohort studies, research platforms, portfolio management, data standardization
Participating in innovative medicines initiative funded neurodegenerative disorder projects—An impact analysis conducted as part of the NEURONET project Hawksworth 2023 NEURONET https://doi.org/10.3389/fneur.2023.1140722 Innovative Medicines Initiative (IMI), neurodegenerative disease, impact, survey, public-private partnerships (PPPs), neurodegenerative disorder
Title Description Type Project  
No entries in table
Website: http://imi-neuronet.org/

 

Back to list